Evidence map›Paper›PMID 33784024›Full record

ArticleCancer medicine2021

Growth and differentiation factor 15 and NF-κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection.

Benjamin A Rybicki, Sudha M Sadasivan, Yalei Chen, Oleksandr Kravtsov, Watchareepohn Palangmonthip, Kanika Arora, Nilesh S Gupta, Sean Williamson, Kevin Bobbitt, Dhananjay A Chitale and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Benjamin A RybickiDepartment of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA.ORCID 0000-0003-3190-3467
Sudha M SadasivanDepartment of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA.
Yalei ChenDepartment of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA.
Oleksandr KravtsovMedical College of Wisconsin, Pathology, Milwaukee, WI, USA.
Watchareepohn PalangmonthipMedical College of Wisconsin, Pathology, Milwaukee, WI, USA.
Kanika AroraDepartment of Pathology, Henry Ford Hospital, Detroit, MI, USA.
Nilesh S GuptaDepartment of Pathology, Henry Ford Hospital, Detroit, MI, USA.
Sean WilliamsonDepartment of Pathology, Henry Ford Hospital, Detroit, MI, USA.
Kevin BobbittDepartment of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA.
Dhananjay A ChitaleDepartment of Pathology, Henry Ford Hospital, Detroit, MI, USA.
Deliang TangDepartment of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA.
Andrew G RundleDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Kenneth A IczkowskiMedical College of Wisconsin, Pathology, Milwaukee, WI, USA.
Henry Ford Hospital · USMedical College of Wisconsin · USColumbia University · US

Funding

GENE-ENVIRONMENT INTERACTION IN PROSTATE CANCERR01ES011126 · NIEHS · HENRY FORD HEALTH SYSTEM · PI RYBICKI, BENJAMIN A. · 2000 to 2017
$8.0M
NIEHS NIH HHS R01 ES011126
6 · The paper itself

Abstract

Growth and differentiation factor 15 (GDF-15), also known as macrophage inhibitory cytokine 1 (MIC-1), may act as both a tumor suppressor and promotor and, by regulating NF-κB and macrophage signaling, promote early prostate carcinogenesis. To determine whether expression of these two inflammation-related proteins affect prostate cancer susceptibility, dual immunostaining of benign prostate biopsies for GDF-15 and NF-κB was done in a study of 503 case-control pairs matched on date, age, and race, nested within a historical cohort of 10,478 men. GDF-15 and NF-κB expression levels were positively correlated (r = 0.39; p < 0.0001), and both were significantly lower in African American (AA) compared with White men. In adjusted models that included both markers, the odds ratio (OR) for NF-κB expression was statistically significant, OR =0.87; p = 0.03; 95% confidence interval (CI) =0.77-0.99, while GDF-15 expression was associated with a nominally increased risk, OR =1.06; p = 0.27; 95% CI =0.96-1.17. When modeling expression levels by quartiles, the highest quartile of NF-κB expression was associated with almost a fifty percent reduction in prostate cancer risk (OR =0.51; p = 0.03; 95% CI =0.29-0.92). In stratified models, NF-κB had the strongest negative association with prostate cancer in non-aggressive cases (p = 0.03), older men (p = 0.03), and in case-control pairs with longer follow-up (p = 0.02). Risk associated with GDF-15 expression was best fit using nonlinear regression modeling where both first (p = 0.02) and second (p = 0.03) order GDF-15 risk terms were associated with significantly increased risk. This modeling approach also revealed significantly increased risk associated with GDF-15 expression for subsamples defined by AA race, aggressive disease, younger age, and in case-control pairs with longer follow-up. Therefore, although positively correlated in benign prostatic biopsies, NF-κB and GDF-15 expression appear to exert opposite effects on risk of prostate tumor development.

Indexed as

AgedAge FactorsBiomarkers, TumorBiopsyBlack or African AmericanCase-Control StudiesConfidence IntervalsGrowth Differentiation Factor 15HumansKallikreinsMacrophagesMaleMiddle AgedNF-kappa B p50 SubunitOdds RatioProstateBiomarkers, TumorGDF15 protein, humanGrowth Differentiation Factor 15KallikreinsKLK3 protein, humanNF-kappa B p50 SubunitNFKB1 protein, humanProstate-Specific AntigenTumor Suppressor ProteinsAfrican Americanscytokineimmunohistochemistryinflammationodds ratio

Identifiers

PMID33784024
PMCPMC8085972
OpenAlexW3149999465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.